ライフサイエンスコーパス: postoperative chemotherapy

1 eoadjuvant chemoradiotherapy do not complete postoperative chemotherapy.

2 node involvement (pN) of primary cancer, and postoperative chemotherapy.

3 val of 90% (77-100) and did not benefit from postoperative chemotherapy.

4 ar invasion, perineural invasion, and use of postoperative chemotherapy.

5 ic factor and is used to guide the choice of postoperative chemotherapy.

6 motherapy followed by definitive surgery and postoperative chemotherapy.

7 d chemotherapy and 27 received both pre- and postoperative chemotherapy.

8 received induction chemotherapy, as well as postoperative chemotherapy.

9 Do all patients need postoperative chemotherapy?

10 excised compared with patients who received postoperative chemotherapy (113 cm vs. 213 cm, P = 0.004

11 a further nine cycles of OxMdG) or standard postoperative chemotherapy (12 cycles of OxMdG).

12 After completing three cycles of postoperative chemotherapy, 216 eligible patients were r

13 extrahepatic disease (P=0.34) or type of pre/postoperative chemotherapy (5-FU-leucovorin vs. FOLFOX/F

14 event-free survival compared with the use of postoperative chemotherapy alone.

15 y; surgery on day 57; and one more course of postoperative chemotherapy and 12 to 18 Gy of concurrent

16 Postoperative chemotherapy and radiation therapy improve

17 Pancreaticoduodenectomy with postoperative chemotherapy and radiation therapy is asso

18 tient was treated by surgical resection with postoperative chemotherapy and radiation.

19 th resected head and neck cancer, concurrent postoperative chemotherapy and radiotherapy significantl

20 Prospective evaluation of whether omitting postoperative chemotherapy and/or switching to a noncros

21 d 1.92); CEA more than 200 ng/mL, absence of postoperative chemotherapy, and extrahepatic disease wer

22 of RER status could affect initial therapy, postoperative chemotherapy, and follow-up.

23 ry by 12 weeks from diagnosis, and modifying postoperative chemotherapy based on histologic response.

24 58-3.72) disease were more likely to receive postoperative chemotherapy compared with older patients.

25 Postoperative chemotherapy did not alter outcomes.

26 aturely after compelling evidence supporting postoperative chemotherapy emerged.

27 ative risk factors for survival and pre- and postoperative chemotherapy exposure were analyzed.

28 Patients received two cycles of postoperative chemotherapy followed by 45 Gy of radiatio

29 testing the feasibility and safety of early postoperative chemotherapy followed by concurrent chemor

30 S-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour sho

31 and debate surrounding the issue of pre- and postoperative chemotherapy for patients with localized s

32 Previous studies suggested that postoperative chemotherapy had not improved the prognosi

33 ant brain tumors were treated with prolonged postoperative chemotherapy in an effort to delay irradia

34 At present, stronger evidence exists for postoperative chemotherapy in early-stage NSCLC.

35 ents after reports of a survival benefit for postoperative chemotherapy in other studies.

36 the addition of ifosfamide and etoposide to postoperative chemotherapy in patients with poorly respo

37 s no consensus about the survival benefit of postoperative chemotherapy in stage II colon cancer.

38 The addition of CRT to postoperative chemotherapy in young children with nonmet

39 For more than three decades, postoperative chemotherapy-initially fluoropyrimidines a

40 of adding secondary cytoreductive surgery to postoperative chemotherapy on progression-free survival

41 anced setting, perioperative chemotherapy or postoperative chemotherapy or chemoradiation improves ou

42 despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical p

43 No patient received pre- or postoperative chemotherapy or radiation therapy.

44 98% (50 of 51) of postoperative chemotherapy patients had T3 or more advan

45 Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, i

46 However, postoperative chemotherapy plus chemoradiotherapy, in th

47 Before this study started, the standard postoperative chemotherapy regimen for stage II-III Wilm

48 ents who will suffer recurrence and for whom postoperative chemotherapy significantly prolonged survi

49 For those patients who require postoperative chemotherapy, standard therapy consists of

50 apy treatments have included the addition of postoperative chemotherapy, the addition of brachytherap

51 outcome of poor responders by modifying the postoperative chemotherapy, their prognosis remains poor

52 Of those receiving any pre- or postoperative chemotherapy, three patients received chem

53 tients were treated with the intent of using postoperative chemotherapy to delay planned irradiation.

54 lung cancer resection and the initiation of postoperative chemotherapy to determine the association

55 nse to neoadjuvant chemotherapy to determine postoperative chemotherapy; to evaluate a uniform histol

56 ates similar to those observed in randomized postoperative chemotherapy trials.

57 Preoperative and postoperative chemotherapy was defined as chemotherapy g

58 Patients in CR received three-drug postoperative chemotherapy, whereas patients not in CR w

59 dition of secondary cytoreductive surgery to postoperative chemotherapy with paclitaxel plus cisplati